Efficacy and Safety of Sotagliflozin by Baseline Renal Function in Adults with Type 1 Diabetes

被引：0
|
作者：
Handelsman, Yehuda
Giaccari, Andrea
Sawhney, Sangeeta
Banks, Phillip L.
Davies, Michael J.
Lapuerta, Pablo
机构：
来源：
DIABETES | 2020年 / 69卷
关键词：
D O I：
10.2337/db20-1100-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1100-P
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes
    Garg, Satish K.
    Henry, Robert R.
    Banks, Phillip
    Buse, John B.
    Davies, Melanie J.
    Fulcher, Gregory R.
    Pozzilli, Paolo
    Gesty-Palmer, Diane
    Lapuerta, Pablo
    Simo, Rafael
    Danne, Thomas
    McGuire, Darren K.
    Kushner, Jake A.
    Peters, Anne
    Strumph, Paul
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (24): : 2337 - 2348
  • [42] Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with Sotagliflozin
    Boeder, Schafer
    Davies, Michael J.
    Mcgill, Janet B.
    Pratley, Richard
    Girard, Manon
    Banks, Phillip
    Pettus, Jeremy
    Garg, Satish
    DIABETES TECHNOLOGY & THERAPEUTICS, 2024, 26 (09) : 618 - 625
  • [43] Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus
    Wilding, John P. H.
    Blonde, Lawrence
    Leiter, Lawrence A.
    Cerdas, Sonia
    Tong, Cindy
    Yee, Jacqueline
    Meininger, Gary
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2015, 29 (03) : 438 - 444
  • [44] Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment
    Hanefeld, Markolf
    Arteaga, Juan M.
    Leiter, Lawrence A.
    Marchesini, Giulio
    Nikonova, Elena
    Shestakova, Marina
    Stager, William
    Gomez-Huelgas, Ricardo
    DIABETES OBESITY & METABOLISM, 2017, 19 (11): : 1594 - 1601
  • [45] Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m2
    Danne, Thomas
    Edelman, Steven
    Frias, Juan Pablo
    Ampudia-Blasco, Francisco Javier
    Banks, Philip
    Jiang, Wenjun
    Davies, Michael J.
    Sawhney, Sangeeta
    DIABETES OBESITY & METABOLISM, 2021, 23 (03): : 854 - 860
  • [46] Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study
    Buse, John B.
    Garg, Satish K.
    Rosenstock, Julio
    Bailey, Timothy S.
    Banks, Phillip
    Bode, Bruce W.
    Danne, Thomas
    Kushner, Jake A.
    Lane, Wendy S.
    Lapuerta, Pablo
    McGuire, Darren K.
    Peters, Anne L.
    Reed, John
    Sawhney, Sangeeta
    Strumph, Paul
    DIABETES CARE, 2018, 41 (09) : 1970 - 1980
  • [47] 12-Week Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Young Adults with Poorly Controlled Type 1 Diabetes (JDRF Study)
    Bode, Bruce W.
    Banks, Phillip
    Sawhney, Sangeeta
    Strumph, Paul
    DIABETES, 2017, 66 : LB39 - LB39
  • [48] An up-to-date evaluation of sotagliflozin for the treatment of type 1 diabetes
    Chatzopoulos, Georgios
    Tziomalos, Konstantinos
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (15) : 1799 - 1803
  • [49] Efficacy and Safety of Mini-dose Glucagon for Treatment of Nonsevere Hypoglycemia in Adults with Type 1 Diabetes
    Haymond, Morey W.
    Dubose, Stephanie
    Rickels, Michael R.
    Wolpert, Howard
    Shah, Viral N.
    Sherr, Jennifer L.
    Weinstock, Ruth S.
    Agarwal, Shivani
    Verdejo, Alandra S.
    Cummins, Martin J.
    Newswanger, Brett
    Beck, Roy W.
    DIABETES, 2017, 66 : A281 - A281
  • [50] Efficacy and safety of ultra-rapid lispro compared to insulin lispro in adults with type 1 diabetes
    Zhou, Z.
    Ma, J.
    Lei, T.
    An, Z.
    Xue, Y.
    Manghi, F. P.
    Garcia, P.
    Xu, J.
    Yuan, Y.
    Yan, X.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S364 - S364
12345